

1 INTRODUCTION

2 *The pharmaceutical workforce in a global health setting*

3 Strengthening access to primary health care services and the health workforce is recognised as essential for progress on
4 the United Nations (UN) Sustainable Development Goal (SDG) 3 and Universal Health Coverage (UHC) by 2030.¹ Delivering
5 quality health care services is dependent on a sufficient and competent health workforce.¹ The World Health Organisation
6 (WHO) estimates a projected shortfall of 18 million health workers by 2030, mostly in low and lower-middle income
7 countries, prompting worldwide strategies to address this challenge; this includes a focus on the current challenges in
8 capacity building for the education, training, and performance of the health workforce.² The WHO-Global strategy for the
9 health care workforce 2030 clearly illustrates that health systems in any country can only function with an available,
10 accessible and acceptable health workforce, equipped with competencies necessary to deliver quality care.³

11 The pharmaceutical workforce plays a key role in improving health outcomes through the responsible use of medicines and
12 optimising effective choice and use.⁴ Pharmaceutical workforce refers to the whole of the pharmacy-related workforce
13 (e.g. registered pharmacist practitioners, pharmaceutical scientists, pharmacy technicians and other pharmacy support
14 workforce cadres, pre-service students/trainees) working in a diversity of settings (e.g. community, hospital, research and
15 development, industry, military, regulatory, academia and other sectors) with a diversity of scope of practice.⁵ Therefore,
16 investment in the development and advancement of the pharmaceutical workforce is imperative across all scopes and
17 settings to address existing gaps related to education, training and performance and progress its infrastructure.⁶

18 From a pharmaceutical services delivery perspective, systematic development of evidence-based early career and
19 foundation training programmes and strategies will ensure better development, training and retention of the pharmacy
20 workforce to meet global health care challenges. In particular, strategies to optimise performance, quality and impact of
21 the pharmaceutical workforce as a primary mechanism for contributing to societal health and well-being, ensuring
22 effective universal health coverage, and building resilience in health systems at all levels.⁷

23 *Pharmaceutical Development Goals for the decade ahead*

24 The global leadership body for pharmacy, the International Pharmaceutical Federation (FIP), launched a set of global
25 pharmaceutical Development Goals (DGs) in September 2020.⁸ These goals are a key resource for transforming the
26 pharmacy profession over the next decade globally, regionally and nationally. They align with the FIP mission to support
27 global health by enabling the advancement of pharmaceutical practice, sciences and education and are set to transform
28 pharmacy in alignment with wider global imperatives underpinning the UN SDGs.⁹

29 The work builds on the previously published pharmaceutical Workforce Development Goals⁶ resulting in a holistic and
30 integrated set of 21 pharmaceutical DGs for transforming global pharmacy. Each of the DGs comprises 3 principal
31 elements: Practice, Science and Workforce. Alongside each element is a set of mechanisms which form tools and structures
32 to facilitate and support the process of transformation.⁹

33 Foundation Training (early career training) is the second of FIP’s Development Goals, that advocates for building
34 infrastructures for the early post-registration (post-licensing) years of the pharmaceutical workforce, as a basis for
35 consolidating initial education and training and progressing the novice workforce towards advanced practice.¹⁰

36 FIP, strengthened by its partnership with WHO and UNESCO, expands initiatives that evolve pharmacy education and
37 workforce development. Through developing policies and tools, the FIP works in alignment with international organisations
38 such as WHO to support building a competent, flexible and adaptable workforce.

39 *A global competency framework for early career pharmacists*

40 The Global Competency Framework (GbCF) version 1 was initially published in 2012 and presents a core set of behavioural
41 and practice-related competencies synthesised from the documents that should be generally applicable to the pharmacy
42 workforce worldwide. The GbCFv1 was subject to an overarching, evidence-led validation process of literature review,
43 evidence/document gathering, consensus group meetings, content validation meetings and an iterative content phase.¹¹
44 Findings from the validation process provided evidence that at the core, there are shared and common capability attributes
45 across both sectors and borders globally. There are similar expectations in the competence and the practice of pharmacists
46 as medicines experts, certainly in early years of career development.⁴

47 The GbCFv1 is divided into clusters, competencies, and behavioural competencies. The GbCFv1 is intended to act as a
48 mapping tool and can be adapted according to the country or local needs. Acting as a mapping tool for the creation of
49 country-specific needs for the development of practice and practitioner professional development, the GbCFv1 can be
50 attached to an assessment grid and, together with appropriate assessment tools.¹²

51 *Competency-based education and training*

52 The GbCFv1 is aimed for pharmacists in post-graduation practice, beyond registration “Day 1” of employment, and
53 encompassing up to (approximately) the first 2-3 years of career development. This is anchored on the premise that
54 pharmacy education (including initial, continuing education and continuing professional development) should ensure
55 pharmacists are equipped for practice in modern and complex health care systems. Practicing in modern and complex
56 health care systems requires contemporary competencies, which early career pharmacists need to develop and practice.¹³

57 As continuing professional development (CPD) is “the process of the ongoing education and development of health care
58 professionals, from initial qualifying education and for the duration of professional life, in order to maintain competence to
59 practice and increase professional proficiency and expertise”,¹⁴ it is essential to acknowledge that competence is a
60 developmental and goal-oriented process of sharpening existing competencies and adding new ones to pharmacists’
61 professional set of skills and attributes.¹⁵ But competence remains a moving trajectory due to a dynamic labour market
62 driven by an array of clinical, social, technological, and ethical transformations¹⁶ coupled with a dramatic increase in
63 preventable and non-communicable diseases and changes in societal expectations from health systems and health
64 workers.¹⁶

65 Competency frameworks such as the FIP GbCF outline generic competencies which act as a reference guide to pharmacists
66 and stakeholders (educators and employers) involved in the development and training of pharmacists. In addition,
67 pharmacists and stakeholders are further encouraged to embrace and adopt concepts of competency-based education and
68 training (CBET) in professional development. In CBET, the focus shifts on performance of pharmacists in the workplace
69 utilising acquired and specific competencies and incorporating competency-based instructional approaches and
70 assessments,^{17, 18} further consolidating knowledge and positively impacting patient care.¹⁹ Competent pharmacists have
71 the potential to improve therapeutic outcomes and patients' quality of life.^{19, 20}

72 In 2019, in response to the increasing trends in health care delivery complexities, and increasing humanitarian emergencies
73 (including natural disasters, political conflicts and emerging risks of both endemic and pandemic crises) the FIP global
74 professional leadership body commissioned a review and re-drafting of the original GbCFv1 to provide enhanced future-
75 proofing and fitness for purpose within a transnational context.

76 The aim of this study was to revise and update the FIP's 2012 Global Competency Framework v1 to reflect contemporary
77 competencies for early-career pharmacists (at the time of conducting the update).


78

79 **METHODS**

80 Please refer to Appendix 1 for a glossary of terms used in the method section.

81 This is a qualitative study that employed four rounds E-Delphi method. E-Delphi is an online method widely used in health
82 and social research to strengthen decision-making processes and reach consensus.²¹ Using established leadership
83 networks, FIP initiated the project with a credible group of international experts. Reviewing and revising the 2012 version
84 of GbCF was conducted through an iterative approach with repeated and synchronised rounds of analysis and revision
85 focusing on the broad competency areas (or clusters) and associated behavioural statements (descriptors of
86 competencies). This iterative process involved recruiting diverse and representative international expert panels to ensure
87 transnational credibility. The iterative revision process was carried out between January and September 2020 and
88 comprised four phases (Figure 1). In each phase, global expertise was sought on designated sections of the GbCF relevant
89 to their area of expertise and experience. After soliciting input from the various groups, the project team reviewed
90 comments and suggestions individually at first then discussed any discrepancies as a group. The project team incorporated
91 the next set of suggestions in the framework and highlighted them for evaluation by the next group of experts. A
92 consensus was reached when there was no further comments or modification received from the consulted experts.

93



94
95 Figure 1: Multi-phased revision process of the FIP GbCF

96
97 **Phase one: Expert education panel review**

98 The initial phase in the revision process was conducted by DG2 Leads (AA, DB and SM). In this phase, DG2 Leads carried out
99 a scoping review of contemporary pharmacists’ roles based on literature search, the existing GbCF as a reference
100 document and the expertise shared by the three DG2 Leads. The DG2 Leads have extensive knowledge and perspectives as
101 each one of them either worked with or trained early career pharmacists in a different country and region. Whilst it was
102 recognised to define a pharmacist’s role is fraught with difficulties, as much seems to depend on context, sector of work,
103 pharmacist’s career stage and experience,²² commonalities were identified and supported by current literature. Data in the
104 form of competency area(s) and relevant behavioural statement(s) were collated and added to the existing GbCF. The
105 information was collated via Microsoft Excel highlighting new and revised behavioural statements. This phase also involved
106 extensive discussion with the GbCF 2012 developers on contemporary competencies (knowledge, skills or values and
107 attitudes) deemed necessary to reflect an expanding and changing role of pharmacists worldwide. The discussion sessions
108 were supplemented with findings from recent research publications and competency frameworks stemming from
109 pharmacy, medical and nursing profession education, and training extracted in Phase one.²³⁻²⁶ Behavioural statements in
110 the original GbCF were also revised to ensure their currency to practice as it is known today, and changes were annotated
111 accordingly (Table 4). The original developers were also given the opportunity to provide their professional comments and
112 revisions.

113 **Phase two: Expert practitioner panel review**

114 In phase two the revision task involved consultations with a constituted panel of global expert practitioners. The panel
115 comprised nominated FIP Global Leads on Advanced and specialist development (FIP DG4), Leadership development (FIP
116 DG6), Advancing integrated services (FIP DG7), Working with others (FIP DG8), Continuing professional development
117 strategies (FIP DG9), and Impact and outcomes (FIP DG 11). Each DG group was tasked to conduct a review of particular
118 competency clusters and behavioural statements that were deemed to align with their area of expertise. The group task
119 outcomes, referenced with information, comments, and revisions, were focused on three relevant issues related to
120 transnational acceptance of the Goal. These were:

121 1) Should the cluster name be linked with "development" rather than "competency"? *e.g. PC competence development,*
122 *Public Health competence development.*

123 2) What is the validity of scope of the current list of competency behaviours, particularly the newly added statements?

124 3) What behaviours are missing from the designated competency cluster?

125 A two-week turnover period was scheduled to allow DG2 Leads to collect data. After consulting the experts from FIP
126 groups and receiving feedback, the Group Leads revised all comments, and incorporated edits and revisions made in the
127 GbCF. In this phase, group Leads systematically reviewed all the validated comments before preparing the Framework for
128 final revision.


129 **Phase three: External review panel**

130 Following the addition of new competencies and revision of existing ones, this phase involved iterative revision by a wider
131 network of educational and practice experts to ensure wider applicability and relevancy of competencies in the revised
132 framework to pharmacy practice worldwide. The external review panel was selected by convenience sampling and
133 comprised 14 experts from Europe, Eastern Mediterranean and Western Pacific. The experience and expertise of the panel
134 included academia, professional education and training, and research in workforce development. This process can be
135 described as iterative consultation. Iterative consulting in this phase was seen as important to further provide validation to
136 the added and modified statements from the perspective of experts in the field. The iterative consultation additionally
137 included external reviewers.²⁷

138 **Phase four: Second round expert education panel review**

139 After phase three consultation and compiling all revisions for updating the GbCF, the new version of the GbCF was re-
140 presented to Phase 1 reviewers (the initial GbCFv 1 developers) for a final review and minor editing. In this final phase,
141 reformatting the GbCFv2 was conducted including a schematic representation of the framework with competency clusters
142 and competency domains (Figure 2).

143
144
145



147
148
149
150

152 Figure 2: Global Competency Framework version 2 competency clusters

153

154 **RESULTS**

155 In September 2020, revisions to the GbCF were completed and an updated version GbCFv2 was developed. The number of
156 behavioural statements increased from 100 to 124 behavioural statements, with 23 competency domains, increasing from
157 20, but remain structured within four broad competency clusters.

158 **New competencies**

159 As an outcome of the methodology, three new competencies were added to the GbCF (emergency response, digital
 160 literacy, and interprofessional collaboration) and one competency was renamed from self-management to: leadership and
 161 self-regulation (Table 2).

162 *Emergency response:*

163 The emergency response competency group was added to the Pharmaceutical Public Health cluster to cover competencies
 164 related to national and international emergencies and crises. With the recent COVID-19 pandemic²⁸ and ongoing health
 165 crisis around the world,²⁹ pharmacists have demonstrated the pivotal role they have in public health preparedness and
 166 response. Therefore, the pharmaceutical workforce, including early career pharmacists, should at least have the minimum
 167 necessary competency to act in response to crisis.³⁰

168 *Digital literacy:*

169 Another competency that was added to the GbCF was digital literacy. This group of competencies was added to the
 170 professional/personal cluster to emphasise the vital role of technology in providing health care services. The use of
 171 technology and digital platforms is incorporated in all health care facilities globally.

172 *Interprofessional collaboration:*

173 That last added competency was interprofessional collaboration. This was also added to the professional/personal cluster.
 174 Collaborative practice within health care teams benefits patient outcomes,³¹ and pharmacists worldwide are expected to
 175 work inter-professionally to provide essential medicines expertise.³¹

176 *Leadership and self-regulation:*

177 Finally, the competency ‘self-management’ was re-named as ‘Leadership and self-regulation’ to incorporate important
 178 aspects of leadership self-regulation which promote time management and prioritisation in the workplace.³²

179

180 Table 2: Distribution of competencies in GbCF 2012 and GbCF 2020

| GbCF 2012 | | GbCF 2020 | |
|---------------------------------|--|---------------------------------|--|
| Cluster | Competencies | Cluster | Competencies |
| 1. Pharmaceutical Public Health | 1.1 Health Promotion 1.2 Medicines information and advice | 1. Pharmaceutical Public Health | 1.1 Emergency response* 1.2 Health promotion 1.3 Medicines information and advice |
| 2. Pharmaceutical Care | 2.1 Assessment of medicines 2.2 Compounding medicines 2.3 Dispensing 2.4 Medicines 2.5 Monitor medicines therapy | 2. Pharmaceutical Care | 2.1 Assessment of medicines 2.2 Compounding medicines 2.3 Dispensing 2.4 Medicines 2.5 Monitor medicines therapy 2.6 Patient consultation and diagnosis |

| | | | |
|--------------------------------|---|--------------------------------|---|
| | 2.6 Patient consultation and diagnosis | | |
| 3. Organisation and Management | 3.1 Budget and reimbursement 3.2 Human resources management 3.3 Improvement of service 3.4 Procurement 3.5 Supply chain and management 3.6 Workplace management | 3. Organisation and Management | 3.1 Budget and reimbursement 3.2 Human resources management 3.3 Improvement of service 3.4 Procurement 3.5 Supply chain management 3.6 Workplace management |
| 4. Professional/Personal | 4.1 Communication skills 4.2 Continuing professional development (CPD) 4.3 Legal and regulatory practice 4.4 Professional and ethical practice 4.5 Quality assurance and research in the workplace 4.6 Self-management | 4. Professional/Personal | 4.1 Communication skills 4.2 Continuing Professional Development (CPD) 4.3 Digital literacy* 4.4 Interprofessional collaboration* 4.5. Leadership and self-regulation** 4.6 Legal and regulatory practice 4.7. Professional and ethical practice 4.8. Quality assurance and research in the workplace |

* New/added competencies

** Modified title/competencies

Additional competency behaviours

Twenty-four new behaviours were added to the GbCF (Table 3). Two new behaviours were added to the new competency 'emergency response'. One new behaviour was added to the competency 'health promotion' to address national and local priorities. Additionally, one new behaviour was added to 'Medicine's information and advice' to ensure competence related to health informatics and proper use of technology. Another two new behaviours were added to the competency 'assessment of medicine' to reflect necessary competencies related to patients' information retrieval and interpretation to ensure optimum patient care.

A behavioural statement related to improving health literacy increasing patient education and counselling was added to 'Patient consultation and diagnosis' competency. Another two behavioural statements were added to 'Supply chain management' and 'Continuing Professional Development (CPD)' competencies to minimize risk of medicines shortages and to highlight the importance of life-long learning, respectively. Four new behaviours were added to the new competency 'Digital literacy' to ensure that the pharmacy workforce is able to identify skills adaptations linked with advancing health care technology. Four new behaviours were included in the new competency 'Interprofessional collaboration' to better enable the pharmacy workforce to work in teams and with other health care professionals.

198 The 'Interprofessional collaboration' competency also includes a fifth behaviour that was moved from the 'Human
 199 resources management' competency found in the GbCF 2012. Three new behaviours were added to the competency
 200 'Leadership and self-regulation' to reflect the importance of emotional intelligence, flexibility and adaptability, as well as
 201 resilience.

202 Finally, four new behaviours were added to the 'Professional and ethical practice' competency. These involved behaviours
 203 related to social accountability and support to patients to make informed choices about medicine use.

204 Table 3: Additional competency behaviours in the GbCFv2 2020

| Competencies | Behaviours |
|---|--|
| 1.1 Emergency response | 1.1.1 Participate in the response to public health emergencies |
| | 1.1.2 Assist the multidisciplinary health care teams in emergency situations |
| 1.2 Health promotion | 1.2.3 Identify and support national and local health priorities and initiatives |
| 1.3 Medicines information and advice | 1.3.3 Support the patient's use of health information technologies and digital communication (including IT driven health solutions) |
| 2.1 Assessment of medicines | 2.1.1 Gather, analyse, research, and interpret information about the patient and patient's medicines-related needs (e.g. indication, effectiveness, safety and adherence) |
| | 2.1.2. Retrieve relevant patient information (including drug history, or immunisation status for example) and record of allergies to medicines and Adverse Drug Reactions (ADR) in medication record |
| 2.6 Patient consultation and diagnosis | 2.6.4 Evaluate, assess, and develop health literacy education and counselling on medicines and health care needs |
| 3.5 Supply chain management | 3.5.7 Mitigate risk of medicines shortages and stock outs through liaison and appropriate communication with health care staff, health care stakeholders, clients/customers and patients |
| 4.2 Continuing Professional Development (CPD) | 4.2.9 Demonstrate engagement/participation in professional development and lifelong learning activities |
| 4.3 Digital literacy | 4.3.1 Identify, manage, organise, store, and share digital information |
| | 4.3.2 Critically appraise, analyse, evaluate, and/or interpret digital information and their sources |
| | 4.3.3 Where applicable, participate in digital health services that promote health outcomes and engage with digital technologies (e.g. social media platforms & mobile applications) to facilitate discussions with the patient and others |
| | 4.3.4 Maintain patient privacy and security of digital information related to the patient and workplace |
| 4.4 Interprofessional collaboration | 4.4.1 Respect and acknowledge the expertise, roles and responsibilities of colleagues and other health professionals |
| | 4.4.2 Participate, collaborate, advise in therapeutic decision-making, and use appropriate referral in a multi-disciplinary team* |
| | 4.4.3 Engage in collaborative practice, research and service provision to optimise patient health outcomes |
| | 4.4.4 Engage in relationship-building with health professionals allowing conflict resolution, teamwork, communication, and consultation |
| | 4.4.5 Demonstrate mutual respect and adopt shared values of the workplace and toward patient care |

| | |
|--|--|
| 4.5. Leadership and self-regulation | 4.5.6 Recognise and describe emotional information about self and others (e.g. self-awareness, self-regulation, motivation, social skills and empathy) |
| | 4.5.7 Demonstrate flexibility and adaptability to a variety of conditions and circumstances |
| | 4.5.8 Recognise when affected by setbacks or stress and manage with effective coping strategies (resilience) |
| 4.7. Professional and ethical practice | 4.7.2 Fulfil duty of care to the patient and the public |
| | 4.7.4 Comply with patient privacy legislation including documentation of information |
| | 4.7.5 Consider available evidence and support the patient to make informed choices about medicine use |
| | 4.7.9 Demonstrate awareness of socially accountable practice (including cultural and social needs; cultural safety, respect, and responsiveness; diversity, equity and inclusiveness). |

* Moved from the 'Human Resources management' competency found in GbCF 2012

Modified behaviours

Table 4 presents the behaviours that were in the GbCF 2012 but were modified and updated in the GbCF 2020.

Table 4: Updated competency behaviours in the GbCFv2 2020

| Competencies | Behaviours | |
|--|--|---|
| | GbCF 2012 | GbCF 2020 |
| 1.2 Health promotion | 1.1.1 Assess the primary health care needs (taking into account the cultural and social setting of the patient) | 1.2.1 Assess the patient's/population's primary health care needs (taking into account the cultural and social setting of the patient/ populations) |
| | 1.1.2 Advise on health promotion, disease prevention and control, and healthy lifestyle | 1.2.2 Advise and provide services directly associated with public health provision ; disease prevention and control (e.g. vaccination services provision); and healthy lifestyle |
| 1.3 Medicines information and advice | 1.2.2 Identify sources, retrieve, evaluate, organise, assess and disseminate relevant medicines information according to the needs of patients and clients and provide appropriate information | 1.3.2 Identify sources, retrieve, evaluate, organise, assess and provide relevant and appropriate medicines information according to the needs of patients and clients |
| 2.1 Assessment of medicines | 2.1.2 Identify, prioritise and act upon medicine-medicine interactions; medicine-disease interactions; medicine-patient interactions; medicines-food interactions | 2.1.3 Identify, prioritise, resolve and follow up on medicine-medicine interactions; medicine-disease interactions; medicine-patient interactions; medicines-food interactions |
| 2.3 Dispensing | 2.3.1 Accurately dispense medicines for prescribed and/or minor ailments and monitor the dispense (re-checking the medicines) | 2.3.1 Accurately dispense medicines for prescribed and/or minor ailments, including an embedded checking process |
| 2.5 Monitor medicines therapy | 2.5.2 Ensure therapeutic medicines monitoring, impact and outcomes (including objective and subjective measures) | 2.5.2 Apply therapeutic medicines monitoring and assess impact, and outcomes (including objective and subjective measures) |
| 2.6 Patient consultation and diagnosis | 2.6.1 Apply first aid and act upon arranging follow-up care | 2.6.1 Support urgent care needs (physical and mental) of patients and others and act upon arranging follow-up care |

| | | |
|---|---|---|
| | 2.6. Assess and diagnose based on objective and subjective measures | 2.6.3 Assess and diagnose based on objective and subjective measures (where applicable) |
| | 2.6.5 Document any intervention (e.g. document allergies, medicines and food in the patient medicines history) | 2.6.6 Document any intervention (e.g. document allergies, such as from medicines and nutrition in the patient's medicines history) |
| 3.1 Budget and reimbursement | 3.1.1 Acknowledge the organisational structure | 3.1.1 Acknowledge the workplace organisational structure |
| | 3.1.3 Ensure appropriate claims for the reimbursement | 3.1.3 Manage appropriate claims for reimbursements |
| 3.2 Human resources management | 3.2.1 Demonstrate organisational and management knowledge (e.g. know, understand and lead on medicines management, risk management, self-management, time management, people management, project management, policy management) | 3.2.1 Demonstrate organisational and management skills (e.g. plan, organise and lead on medicines management; risk management; self-management; time management; people management; project management; policy management.) |
| 3.4 Procurement | 3.4.5 Select reliable supplies of high-quality products (including appropriate selection process, cost effectiveness, timely delivery) | 3.4.5 Identify and select reliable supplier(s) |
| | | 3.4.6 Select reliable supply of high-quality products (including appropriate selection and procurement processes, cost effectiveness, timely delivery) |
| 3.5 Supply chain management | 3.5.2 Ensure accurate verification of rolling stocks | 3.5.2 Verify the accuracy of rolling stocks |
| 4.1 Communication skills | 4.1.3 Demonstrate cultural awareness and sensitivity | 4.1.3 Tailor communication that is appropriate to the patient's needs (including health literacy, cultural or language barriers, social needs, and emotional status) |
| | 4.1.4 Tailor communications to patient needs | |
| 4.2 Continuing Professional Development (CPD) | 4.2.6 Identify learning needs | 4.2.4 Identify learning and development needs |
| | 4.2.4 Evaluate learning | 4.2.5 Evaluate learning and development progress |
| | 4.2.5 Identify if expertise needed outside the scope of knowledge | 4.2.6 Identify if expertise is needed outside current scope of knowledge |
| 4.6 Legal and regulatory practice | 4.3.2 Apply knowledge in relation to the principals of business economics and intellectual property rights including the basics of patent interpretation | 4.6.2 Apply the principles of business economics and intellectual property rights including the basics of patent interpretation |
| | 4.3.5 Demonstrate knowledge in marketing and sales | 4.6.5 Apply the principles of marketing and sales |
| | 4.3.7 Understand the steps needed to bring a medicinal product to the market including the safety, quality, efficacy, and pharmacoeconomic assessments of the product | 4.6.7 Recognise the steps needed to bring a medical device or medicine to the market including the safety, quality, efficacy and pharmacoeconomic assessments of the product |
| 4.7. Professional and ethical practice | 4.4.1 Demonstrate awareness of local/national codes of ethics | 4.7.1 Demonstrate awareness and employment of local/national codes of ethics |
| | 4.4.2 Ensure confidentiality (with the patient and other health care professional) | 4.7.3 Maintain privacy and confidentiality (with the patient and other health care professionals) |
| | 4.4.5 Take responsibility of own action and for patient care | 4.7.8 Demonstrate professional responsibility for all decisions made and actions taken |
| | 4.4.4 Recognise own professional limitation | 4.7.7 Recognise professional limitations of self and others in the team |
| 4.8. Quality assurance and | 4.5.1 Apply research findings and understand the benefits risk (e.g. pre- | 4.8.1 Apply research findings and understand risk-benefit analyses (e.g. pre-clinical, clinical trials, |

| | | |
|--------------------------------------|--|---|
| research in the workplace | clinical, clinical trials, experimental clinical-pharmacological research and risk management | experimental clinical pharmacological research, and risk management) |
| | 4.5.2 Audit quality of service (ensure that they meet local and national standards and specifications) | 4.8.2 Audit quality of service (meet local and national standards and specifications) |
| | 4.5.5 Ensure medicines are not counterfeit and quality standards | 4.8.5 Ensure medicines are not counterfeit and adhere to quality standards |
| 4.5. Leadership and self-regulation* | 4.6.4 Ensure punctuality | 4.5.4 Prioritise work , practice punctuality and time management |
| | 4.6.5 Prioritise work and implement innovative ideas | 4.5.5 Develop , implement and monitor innovative ideas |

*Previously named self-management

Final framework

Table 5 presents the final clusters, competencies and behaviours in the GbCF 2012.

Table 5: FIP Global Competency Framework (GbCF) version 2 - 2020

| 1. Pharmaceutical Public Health | |
|--------------------------------------|--|
| Competencies | Behaviours |
| 1.1 Emergency response | 1.1.1 Participate in the response to public health emergencies |
| | 1.1.2 Assist the multidisciplinary health care teams in emergency situations |
| 1.2 Health promotion | 1.2.1 Assess the patient's/population's primary health care needs (taking into account the cultural and social setting of the patient/populations) |
| | 1.2.2 Advise and provide services directly associated with public health provision; disease prevention and control (e.g. vaccination services provision); and healthy lifestyle. |
| | 1.2.3 Identify and support national and local health priorities and initiatives |
| 1.3 Medicines information and advice | 1.3.1 Counsel the patient/population on the safe and rational use of medicines and devices (including the selection, use, contraindications, storage, and side effects of non-prescription and prescription medicines) |
| | 1.3.2 Identify sources, retrieve, evaluate, organise, assess and provide relevant and appropriate medicines information according to the needs of patients and clients |
| | 1.3.3 Support the patient's use of health information technologies and digital communication (including IT driven health solutions) |
| 2. Pharmaceutical Care | |
| Competencies | Behaviours |
| 2.1 Assessment of medicines | 2.1.1 Gather, analyse, research, and interpret information about the patient and patient's medicines-related needs (e.g. indication, effectiveness, safety and adherence) |
| | 2.1.2. Retrieve relevant patient information (including drug history, or immunisation status for example) and record of allergies to medicines and Adverse Drug Reactions (ADR) in medication record |
| | 2.1.3 Identify, prioritise, resolve and follow up on medicine-medicine interactions; medicine-disease interactions; medicine-patient interactions; medicines-food interactions |
| | 2.1.4 Appropriately select medicines (e.g. according to the patient, hospital, government policy, etc) |

| | |
|--|--|
| 2.2 Compounding medicines | 2.2.1 Prepare pharmaceutical medicines (e.g. extemporaneous, cytotoxic medicines), determine the requirements for preparation (calculations, appropriate formulation, procedures, raw materials, equipment etc.) |
| | 2.2.2 Compound under the good manufacturing practice for pharmaceutical (GMP) medicines |
| 2.3 Dispensing | 2.3.1 Accurately dispense medicines for prescribed and/or minor ailments, including an embedded checking process |
| | 2.3.2 Accurately report defective or substandard medicines to the appropriate authorities |
| | 2.3.3 Appropriately validate prescriptions, ensuring that prescriptions are correctly interpreted and legal |
| | 2.3.4 Dispense devices (e.g. Inhaler or a blood glucose meter) |
| | 2.3.5 Document and act upon dispensing errors |
| | 2.3.6 Implement and maintain a dispensing error reporting system and a 'near misses' reporting system |
| | 2.3.7 Label the medicines (with the required and appropriate information) |
| | 2.3.8 Learn from and act upon previous 'near misses' and 'dispensing errors' |
| 2.4 Medicines | 2.4.1 Advise patients on proper storage conditions of the medicines and ensure that medicines are stored appropriately (e.g. humidity, temperature, expiry date, etc.) |
| | 2.4.2 Appropriately select medicines formulation and concentration for minor ailments (e.g. diarrhoea, constipation, cough, hay fever, insect bites, etc.) |
| | 2.4.3 Ensure appropriate medicines, route, time, dose, documentation, action, form and response for individual patients |
| | 2.4.4 Package medicines to optimise safety (ensuring appropriate re-packaging and labelling of the medicines) |
| 2.5 Monitor medicines therapy | 2.5.1 Apply guidelines, medicines formulary system, protocols, and treatment pathways |
| | 2.5.2 Apply therapeutic medicines monitoring and assess impact, and outcomes (including objective and subjective measures) |
| | 2.5.3 Identify, prioritise, and resolve medicines management problems (including errors) |
| 2.6 Patient consultation and diagnosis | 2.6.1 Support urgent care needs (physical and mental) of patients and others and act upon arranging follow-up care |
| | 2.6.2 Appropriately refer the patient or carer |
| | 2.6.3 Assess and diagnose based on objective and subjective measures (where applicable) |
| | 2.6.4 Evaluate, assess, and develop health literacy education and counselling on medicines and health care needs |
| | 2.6.5 Discuss and agree with the patient on the appropriate use of medicines, taking into account patients' preferences |
| | 2.6.6 Document any intervention (e.g. document allergies, such as from medicines and nutrition in the patient's medicines history) |
| | 2.6.7 Obtain, reconcile, review, maintain and update relevant patient medication and disease history |
| 3. Organisation and Management | |
| Competencies | Behaviours |
| 3.1 Budget and reimbursement | 3.1.1 Acknowledge the workplace organisational structure |
| | 3.1.2 Effectively set and apply budgets |
| | 3.1.3 Manage appropriate claims for reimbursements |
| | 3.1.4 Ensure financial transparency |

| | |
|---------------------------------|---|
| | 3.1.5 Ensure proper reference sources for service reimbursement |
| 3.2 Human resources management | 3.2.1 Demonstrate organisational and management skills (e.g. plan, organise and lead on medicines management; risk management; self-management; time management; people management; project management; policy management.) |
| | 3.2.2 Identify and manage human resources and staffing issues |
| | 3.2.3 Recognise and manage the potential of each staff member and utilise systems for performance management (e.g. conduct staff appraisals) |
| | 3.2.4 Recognise the value of pharmacy team and of a multidisciplinary team |
| | 3.2.5 Support and facilitate staff training and continuing professional development |
| 3.3 Improvement of service | 3.3.1 Identify, implement, and monitor new services (according to local needs) |
| | 3.3.2 Resolve, follow up and prevent medicines related problems |
| 3.4 Procurement | 3.4.1 Access reliable information and ensure the most cost-effective medicines in the right quantities with the appropriate quality |
| | 3.4.2 Develop and implement contingency plans for shortages |
| | 3.4.3 Efficiently link procurement to formulary, to push/pull system (supply chain management) and payment mechanisms |
| | 3.4.4 Ensure there is no conflict of interest |
| | 3.4.5 Identify and select reliable supplier(s) |
| | 3.4.6 Select reliable supply of high-quality products (including appropriate selection and procurement processes, cost effectiveness, timely delivery) |
| | 3.4.7 Supervise procurement activities |
| | 3.4.8 Understand the tendering methods and evaluation of tender bids |
| 3.5 Supply chain management | 3.5.1 Demonstrate knowledge in store medicines to minimise errors and maximise accuracy |
| | 3.5.2 Verify the accuracy of rolling stocks |
| | 3.5.3 Ensure effective stock management and running of service with the dispensary |
| | 3.5.4 Ensure logistics of delivery and storage |
| | 3.5.5 Implement a system for documentation and record keeping |
| | 3.5.6 Take responsibility for quantification and supply chain forecasting |
| | 3.5.7 Mitigate risk of medicines shortages and stock outs through liaison and appropriate communication with health care staff, health care stakeholders, clients/customers and patients |
| 3.6 Workplace management | 3.6.1 Address and manage day-to-day management issues |
| | 3.6.2 Demonstrate the ability to take accurate and timely decisions and make appropriate judgements |
| | 3.6.3 Ensure the production schedules are appropriately planned and managed |
| | 3.6.4 Ensure the work time is appropriately planned and managed |
| | 3.6.5 Improve and manage the provision of pharmaceutical services |
| | 3.6.6 Recognise and manage pharmacy resources (e.g. financial, infrastructure) |
| 4. Professional/Personal | |
| Competencies | Behaviours |
| 4.1 Communication skills | 4.1.1 Communicate clearly, precisely, and appropriately while being a mentor or tutor |

| | |
|---|--|
| | 4.1.2 Communicate effectively with health and social care staff, support staff, patients, carer, family relatives and clients/customers, using lay terms and checking understanding |
| | 4.1.3 Tailor communication that is appropriate to the patient's needs (including health literacy, cultural or language barriers, social needs, and emotional status) |
| | 4.1.4 Use appropriate communication skills (e.g. verbal and non-verbal) to establish and maintain rapport with the patient and others including when communicating through digital and electronic platforms |
| 4.2 Continuing Professional Development (CPD) | 4.2.1 Document CPD activities |
| | 4.2.2 Engage with students/interns/residents |
| | 4.2.3 Evaluate accuracy of knowledge and skills |
| | 4.2.4 Identify learning and development needs |
| | 4.2.5 Evaluate learning and development progress |
| | 4.2.6 Identify if expertise is needed outside current scope of knowledge |
| | 4.2.7 Recognise own limitations and act upon them |
| | 4.2.8 Reflect on performance |
| | 4.2.9 Demonstrate engagement/participation in professional development and lifelong learning activities |
| 4.3 Digital literacy | 4.3.1 Identify, manage, organise, store, and share digital information |
| | 4.3.2 Critically appraise, analyse, evaluate, and/or interpret digital information and their sources |
| | 4.3.3 Where applicable, participate in digital health services that promote health outcomes and engage with digital technologies (e.g. social media platforms & mobile applications) to facilitate discussions with the patient and others |
| | 4.3.4 Maintain patient privacy and security of digital information related to the patient and workplace |
| 4.4 Interprofessional collaboration | 4.4.1 Respect and acknowledge the expertise, roles and responsibilities of colleagues and other health professionals |
| | 4.4.2 Participate, collaborate, advise in therapeutic decision-making, and use appropriate referral in a multi-disciplinary team |
| | 4.4.3 Engage in collaborative practice, research and service provision to optimise patient health outcomes |
| | 4.4.4 Engage in relationship-building with health professionals allowing conflict resolution, teamwork, communication, and consultation |
| | 4.4.5 Demonstrate mutual respect and adopt shared values of the workplace and toward patient care |
| 4.5. Leadership and self-regulation | 4.5.1 Apply assertiveness skills (inspire confidence) |
| | 4.5.2 Demonstrate leadership and practice management skills, initiative and efficiency |
| | 4.5.3 Document risk management (critical incidents) |
| | 4.5.4 Prioritise work, practice punctuality and time management |
| | 4.5.5 Develop, implement and monitor innovative ideas |
| | 4.5.6 Recognise and describe emotional information about self and others (e.g. self-awareness, self-regulation, motivation, social skills and empathy) |
| | 4.5.7 Demonstrate flexibility and adaptability to a variety of conditions and circumstances |

| | |
|--|--|
| | 4.5.8 Recognise when affected by setbacks or stress and manage with effective coping strategies (resilience) |
| 4.6 Legal and regulatory practice | 4.6.1 Apply regulatory affairs and the key aspects of pharmaceutical registration and legislation |
| | 4.6.2 Apply the principles of business economics and intellectual property rights including the basics of patent interpretation |
| | 4.6.3 Be aware of and identify the new medicines coming to the market |
| | 4.6.4 Comply with legislation for drugs with the potential for abuse |
| | 4.6.5 Apply the principles of marketing and sales |
| | 4.6.6 Engage with health and medicines policies |
| | 4.6.7 Recognise the steps needed to bring a medical device or medicine to the market including the safety, quality, efficacy and pharmacoeconomic assessments of the product |
| 4.7. Professional and ethical practice | 4.7.1 Demonstrate awareness and employment of local/national codes of ethics |
| | 4.7.2 Fulfil duty of care to the patient and the public |
| | 4.7.3 Maintain privacy and confidentiality (with the patient and other health care professionals) |
| | 4.7.4 Comply with patient privacy legislation including documentation of information |
| | 4.7.5 Consider available evidence and support the patient to make informed choices about medicine use |
| | 4.7.6 Obtain patient consent (it can be implicit on occasion) |
| | 4.7.7 Recognise professional limitations of self and others in the team |
| | 4.7.8 Demonstrate professional responsibility for all decisions made and actions taken |
| | 4.7.9 Demonstrate awareness of socially accountable practice (including cultural and social needs; cultural safety, respect, and responsiveness; diversity, equity and inclusiveness). |
| 4.8. Quality assurance and research in the workplace | 4.8.1 Apply research findings and understand risk-benefit analyses (e.g. pre-clinical, clinical trials, experimental clinical pharmacological research, and risk management) |
| | 4.8.2 Audit quality of service (meet local and national standards and specifications) |
| | 4.8.3 Develop and implement standing Operating Procedures (SOP's) |
| | 4.8.4 Ensure appropriate quality control tests are performed and managed appropriately |
| | 4.8.5 Ensure medicines are not counterfeit and adhere to quality standards |
| | 4.8.6 Identify and evaluate evidence-base to improve the use of medicines and services |
| | 4.8.7 Identify, investigate, conduct, supervise and support research at the workplace (enquiry-driven practice) |
| | 4.8.8 Implement, conduct and maintain a reporting system of pharmacovigilance (e.g. report Adverse Drug Reactions) |
| | 4.8.9 Initiate and implement audit research activities |

220

221 **DISCUSSION**

222 This study aimed to revise and update the FIP's 2012 Global Competency Framework v1 to reflect contemporary

223 competencies for early-career pharmacists. After a four-round Delphi process with 29 international experts, the number of

224 behavioural statements increased from 100 to 124 behavioural statements, with 23 competency domains, increasing from
225 20, but remain structured within four broad competency clusters.

226 Competency frameworks in health professions education and training are used to help practitioners navigate and advance
227 their careers.^{12, 24, 33-35} In addition to the GbCF, in 2021 FIP developed the FIP Global Humanitarian Competency Framework
228 to provide an international competency framework for pharmacists working in the humanitarian arena, that would be used
229 to guide education and training programmes in this increasingly important field of practice.³⁶ More recently, in a global
230 effort to consolidate CBET for healthcare professionals and provide structural support, the WHO published the Global
231 Competency and Outcomes Framework for Universal Health Coverage,³⁵ to advance progress towards UHC through
232 alignment of health worker education approaches with population health needs and health system demands.³⁵ In
233 pharmacy, pharmacists' early career development can be supported by these frameworks and specifically the FIP GbCF has
234 been used as a base in several countries for the development and implementation of their own frameworks.^{37, 38,39}

235 Whilst the revision of the original FIP GbCF did not change the overall structure of the revised framework, the number of
236 competencies and associated behavioural statements increased due to important additions. These included emergency
237 response, digital literacy, interprofessional collaboration and an expansion of leadership and self-regulation.

238 Pharmacists and pharmacies remain crucial for public access to medicines expertise and public health delivery; however,
239 they are also uniquely positioned to serve patients impacted by disasters such as natural disasters; infectious diseases; and
240 man-made disasters.⁴⁰ Research on the role of pharmacists in emergency response to disasters⁴¹ and humanitarian crisis⁴²
241 is not lacking. Pharmacists have pivotal roles in the prevention, preparedness, response, and recovery to disasters and
242 shared decision-making process during crises.⁴³ These 'non-traditional' roles during the COVID-19 pandemic have been
243 amplified with additional services in vaccination and supply chain management but also where humanitarian crises have
244 worsened. However, professional support and further training of pharmacists in emergency response and preparedness,
245 and associated knowledge and skills remain limited.⁴¹ The pharmaceutical workforce, including early career pharmacists,
246 needs to have access to a necessary competency framework to act in response to a crisis – making “emergency response” a
247 significant new addition to the GbCF.

248 Building on this, the FIP Global Humanitarian Competency Framework was produced as a further, more advanced,
249 extension as a developmental framework designed to be used for and by pharmacists specifically working in the
250 humanitarian arena.³⁶ In conjunction with the revised GbCF, both frameworks ensure that an “adopt and/or adapt”
251 approach for implementation can be applied at global, regional, national and organisational levels. The adopt and/or adapt
252 method is centred on the concept of progressive evidence-led development without requiring duplication or replication,
253 whereby contextual and situational specifics around practice, professional, and regulatory circumstances can be adapted
254 from what has been shown to work in practice. Equally important is having a digitally equipped pharmaceutical workforce
255 that is able to face the many challenges of digital technologies incorporated in patient care and health services.

256 Pharmacists must be prepared with the knowledge and skills in digital technology to fulfil their roles efficiently and
257 effectively. We have all been disrupted by the COVID-19 pandemic and forced to integrate digital technology into our lives
258 to sustain our professional and social demands and wants. Subsequently, adding behavioural statements on digital literacy
259 would also apply to pharmacists needing baseline guidance on digital competencies. The new foundational competencies
260 represent actions that pharmacists can perform when dealing with digital inquiries/services/products particularly related
261 to digital health provision. These competencies outline what pharmacists may need to identify and manage to critically
262 appraise and participate in digital health, and to maintain privacy and security of digital information. The FIP DG 20 on
263 digital health specifically focuses on enablers of digital transformation within the pharmaceutical workforce and on
264 effective processes to facilitate the development of a digitally literate workforce.

265 The World Health Organization projected shortfall of 15 million health workers by 2030, mostly in low- and lower-middle
266 income countries, is alarming.⁴⁴ Pharmacists, in particular, are lacking in the workforce in many countries.⁵ Efforts for
267 transforming and scaling up health professionals' education and training including interprofessional education have been
268 advocated by WHO and resonated by FIP and the profession globally.³¹ In addition, interprofessional education and training
269 needs to be strengthened to advance team-based approaches promoting holistic patient centered care and engagement
270 between health care professions. Five behavioural statements were added to the GbCFv2 covering pertinent aspects of
271 interprofessional collaboration for professional development ranging from demonstrating mutual respect, building
272 relationships and effectively engaging in collaborative practice.

273 Other vital skills early career pharmacists must acquire are leadership and self-regulation. Self-regulation is "an ability to
274 control responses within the self- It is both behavioural (personality) and biological (temperament/disposition)".⁴⁵ Optimal
275 self-regulation is directly related to how well performers manage novel events, a capacity that is influenced by
276 temperament, early developmental experiences, and personality traits.⁴⁵ Pharmacists like other health care workers have
277 leadership, mentoring, educator and team-based roles that need to be developed and promoted from early years in
278 practice. But pharmacists around the world are consistently being challenged by numerous factors that make their work
279 conditions stressful such as high workload, low job control, job dissatisfaction and stressful workplaces.^{46, 47} At the same
280 time, there is the basic assumption that, if employees are well educated for their profession (in this case pharmacists), they
281 are assumed to be willing and able to autonomously regulate their job tasks responsibly, solve daily problems and
282 proactively ask feedback from colleagues if necessary.⁴⁸ Early career pharmacists require to demonstrate a level of self-
283 awareness, responsibility and self-management that will allow them to remain calm in challenging situations and respond
284 or practise more effectively, both independently and within teams or groups.

285 The incorporation of mental health triage and first aid in addition to physical first aid is important to highlight in the revised
286 GbCF. According to the WHO one in every eight people in the world live with mental disorders.⁴⁹ Pharmacists, in their
287 expanding roles, are accessible to provide drug expertise and play an important part in collaborative mental health care
288 including provision of mental health first aid.⁵⁰ This has been added in point 2.6.1 "Support urgent care needs (physical and
289 mental) of patients and others and act upon arranging follow-up care".

290 Foundation training is needed by all regulated health care professionals and early career pharmacists are no exception as
291 they transition towards more advanced stages of practice. To support pharmacists in their transitional phase, it is
292 recommended that professional pharmacy organisations and regulators have a competency framework to support
293 pharmacist professional development and career progression. The GbCFv2 is designed to be adopted and adapted for
294 registered pharmacists to assist with their career progression. The implementation of the GbCFv2 not only supports
295 pharmacists in their career progression but is crucial for professional bodies to progress towards meeting the FIP Global
296 Vision for Pharmaceutical Workforce & Education⁵¹ and the FIP Development Goals (FIP DGs), particularly FIP DG 2 focused
297 on early career training strategy. The GbCF supports and complements progression of the pharmaceutical workforce
298 related to other DGs such as advanced and specialist development; competency development; leadership development;
299 advancing integrated services, working with others; continuing professional development strategies and medicines
300 expertise.

301 A competency developmental framework meets a number of functional purposes ranging from curriculum development
302 and pre-registration programmes, CPD, development of specialisation, and advanced practice, as well as a benchmark for
303 society by stating the professional role of a pharmacist.⁵² However, this can only be achieved with support from pharmacy
304 leaders and relevant stakeholders to formulate policies related to the implementation of competency frameworks and
305 foundation training strategies. FIP's Workforce Transformation Programme (WTP) is a practical and flexible model, which
306 will: assist countries in assessing their individual pharmacy workforce needs and priorities; support them to develop needs-
307 based national workforce strategies and infrastructure; and provide co-created solutions, tools, mechanisms and resources
308 for implementation. FIP also supports its members and the wider profession community through its dissemination
309 strategies of the GbCF and other developmental frameworks and resources including an online catalogue of resources (the
310 FIP Development Goals microsite) which hosts case studies, publications and research projects in various countries where
311 such frameworks are being applied in practice, and for workforce development and education.

312 Strengths of our research on this new revision are the engagement with internal experts representing a range of national
313 professional environments and pharmaceutical care delivery cultures. This credibility lends weight to the transnational
314 generalisability of the framework. One limitation is that in the revision of the framework, it may not have been possible to
315 capture all competencies, services, and roles pharmacists are engaged with at the time. However, we argue this is not the
316 aim of the GbCF; rather it is to represent a generic, comprehensive, framework from which nationalised specifics can be
317 applied. The GbCF may also outline competencies that are irrelevant to pharmacists' scope of practice in particular
318 contexts or countries. However, it is encouraged to view these as enabling competencies to support pharmacists in
319 providing a wider scope of services to patients and enhancing professional performance.⁵³ The GbCF version 2 remains a
320 dynamic and relevant framework that will be updated every 5-8 years to reflect new competencies for contemporary and
321 essential pharmacy services in practice and inclusive of all settings.

322 **Conclusions**

323 In this study, the FIP GbCF original version of 2012 was revised and updated which resulted in the production of a second
324 version composed of 124 behavioural statements embedded in four broad competency clusters. The validated framework
325 is intended to act as a mapping tool for pharmacists to progress towards effective and sustained performance and to
326 prepare them for advanced and specialist roles and services. With a global perspective in mind, the GbCF ensures that an
327 “adopt and adapt” approach for implementation can be consistently applied at global, regional, national and organisational
328 levels.

329 **Acknowledgements**

330 The authors wish to thank all the review panels for their contribution to reviewing the FIP Global Competency Framework.

331

References:

332

1. World Health Organization (WHO). *Global strategy on human resources for health: Workforce 2030*. Geneva. 2016.

333

<https://apps.who.int/iris/bitstream/handle/10665/250368/?sequence=1>

334

2. Limb M. World will lack 18 million health workers by 2030 without adequate investment, warns UN. *BMJ*.

335

2016;354:i5169. doi:10.1136/bmj.i5169

336

3. World Health Organization (WHO). *Health workforce requirements for universal health coverage and the sustainable development goals*. (human resources for health observer, 17). Geneva. 2016.

337

<https://apps.who.int/iris/bitstream/handle/10665/250330/9789241511407-eng.pdf> Accessed 11.07. 2022.

338

339

4. Bruno A, Bates I, Brock T, Anderson C. Towards a global competency framework. *Am J Pharm Educ*. 2010;74(3):56.

340

5. International Pharmaceutical Federation (FIP). *Pharmacy workforce intelligence: Global trends report*. The Hague.

341

International Pharmaceutical Federation; 2018. <https://www.fip.org/file/2077> Accessed 11.07.2022.

342

6. Bader L, Bates I, Schneider P, Charman W. *Transforming pharmacy and pharmaceutical sciences education in the context of workforce development*. The Hague. International Pharmaceutical Federation; 2017.

343

<https://www.fip.org/file/2077> Accessed 29.07.2022.

344

345

7. World Health Organization (WHO). Strengthening health systems for universal health coverage.

346

<http://www.emro.who.int/annual-report/2017/strengthening-health-systems.html> (Accessed 11.07.2022).

347

8. Development goals to support transformation of entire pharmacy profession launched by FIP. International

348

Pharmaceutical Federation,; 2020. Accessed 12.08.2022. [https://www.fip.org/press-releases?press=item&press-](https://www.fip.org/press-releases?press=item&press-item=76)

349

[item=76](https://www.fip.org/press-releases?press=item&press-item=76)

350

9. International Pharmaceutical Federation (FIP). *The FIP Development Goals: Transforming global pharmacy*. The

351

Hague. International Pharmaceutical Federation; 2020. <https://www.fip.org/file/4793> Accessed 12.08.22.

352

10. International Pharmaceutical Federation (FIP). Development Goal2: Early career training strategy.

353

11. Bruno AF. *The feasibility, development and validation of a global competency framework for pharmacy education*. PhD

354

Thesis. University of London.; 2011.

355

12. Core Committee- Institute for International Medical Education. Global minimum essential requirements in medical

356

education. *Med Teach*. 2002;24(2):130-5. doi:10.1080/01421590220120731

357

13. International Pharmaceutical Federation. *A Global Competency Framework*. The Hague, NETH. 2012.

358

https://www.fip.org/files/fip/PharmacyEducation/GbCF_v1.pdf Accessed 19.08.22.

359

14. International Pharmaceutical Federation (FIP). *Continuing professional development/continuing education in*

360

pharmacy: global report. The Hague, . International Pharmaceutical Federation; 2014.

361

[https://www.fip.org/file/1407#:~:text=Federation%20\(FIP\)%20in%202002%20defines,PART%20](https://www.fip.org/file/1407#:~:text=Federation%20(FIP)%20in%202002%20defines,PART%20) Accessed 17.08.22.

362

15. Bajis D, Chaar B, Moles R. Rethinking Competence: a nexus of Educational Models in the Context of Lifelong Learning.

363

Pharmacy. 2020;8(2):81.

364

16. Austin Z. Competency and its many meanings. *Pharmacy (Basel, Switzerland)*.

365

2019;7(27)doi:10.3390/pharmacy7020037

366

17. Bajis D, Chaar B, Basheti IA, Moles R. Pharmacy students' medication history taking competency: Simulation and

367

feedback learning intervention. *Curr Pharm Teach Learn*. 2019;11(10):1002-1015. doi:10.1016/j.cptl.2019.06.007

368

18. Koster A, Schalekamp T, Meijerman I. Implementation of competency-based pharmacy education (CBPE). *Pharmacy*

369

2017;5(1):10. doi:10.3390/pharmacy5010010

370

19. Bisgaard CH, Rubak SLM, Rodt SA, Petersen JAK, Musaeus P. The effects of graduate competency-based education and

371

mastery learning on patient care and return on investment: a narrative review of basic anesthetic procedures. *BMC*

372

Med Educ. 2018;18(1):154. doi:10.1186/s12909-018-1262-7

- 373 20. McLaughlin JE, Bush AA, Rodgers PT, et al. Exploring the requisite skills and competencies of pharmacists needed for
374 success in an evolving health care environment. *Am J Pharm Educ.* 2017;81(6):116. doi:10.5688/ajpe816116
- 375 21. Msibi PN, Mogale R, De Waal M, Ngcobo N. Using e-Delphi to formulate and appraise the guidelines for women's
376 health concerns at a coal mine: A case study. *Curatationis.* 2018;41(1):e1-e6. doi:10.4102/curatationis.v41i1.1934
- 377 22. Waterfield J. Is Pharmacy a Knowledge-Based Profession? *Am J Pharm Educ.* 2010;74(3):Article 50.
- 378 23. Global minimum essential requirements in medical education. *Med Teach.* 2002;24(2):130-5.
379 doi:10.1080/01421590220120731
- 380 24. Royal College of Physicians and Surgeons of Canada. CanMEDS 2015 Physician Competency Framework. Royal College
381 of Physicians and Surgeons of Canada: Ottawa, ON, Canada, 2015.
382 <https://canmeds.royalcollege.ca/en/framework#:~:text=CanMEDS%20is%20an%20educational%20framework,standards%20of%20the%20Royal%20College>. (Accessed 17.07.22).
- 384 25. Benzian H, Greenspan JS, Barrow J, et al. A competency matrix for global oral health. *J Dent Educ.* 2015;79(4):353-61.
- 385 26. World Health Organization (WHO). *Midwifery educator core competencies.* 2013.
386 <https://www.who.int/publications/i/item/midwifery-educator-core-competencies> Accessed 9.9.2022.
- 387 27. Mill D PA, Johnson J, D'Lima D, Lee K, Seubert L, Salter S, Clifford R. *Enhancing Quality in Pharmacy Practice (EQiPP)*
388 *Project. Phase 2 report.* Ltd PSoA.
- 389 28. World Health Organization (WHO). WHO Director-General's opening remarks at the media briefing on COVID-19 - 11
390 March 2020. <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020> (Accessed 25.05.22).
- 392 29. United Nations foundation. Global health. United Nations Foudation. https://unfoundation.org/what-we-do/issues/global-health/?gclid=CjwKCAjw5s6WBhA4EiwACGncZYtydP32jtXOoB7LXx29taygKy4aPfu07PUAdQZ9VgSeUtB2S8rHhoCdacQAvD_BwE (Accessed 20.07.22).
- 396 30. Vardanyan H, Mosegui GBG, Miranda ES. Skills and Core Competencies of Pharmacists in Humanitarian Assistance.
397 *Prehosp Disaster Med.* 2018;33(3):266-272. doi:10.1017/s1049023x18000304
- 398 31. Bosch B, Mansell H. Interprofessional collaboration in health care: Lessons to be learned from competitive sports. *Can*
399 *Pharm J (Ott).* 2015;148(4):176-9. doi:10.1177/1715163515588106
- 400 32. Reed BN, Klutts AM, Mattingly TJ. A Systematic Review of Leadership Definitions, Competencies, and Assessment
401 Methods in Pharmacy Education. *Am J Pharm Educ.* 2019;83(9):7520. doi:10.5688/ajpe7520
- 402 33. Udoh A, Bruno-Tomé A, Ernawati DK, Galbraith K, Bates I. The development, validity and applicability to practice of
403 pharmacy-related competency frameworks: A systematic review. *Res Social Adm Pharm.* 2021;17(10):1697-1718.
404 doi:10.1016/j.sapharm.2021.02.014
- 405 34. Udoh A, Bruno-Tomé A, Ernawati DK, Galbraith K, Bates I. The effectiveness and impact on performance of pharmacy-
406 related competency development frameworks: A systematic review and meta-analysis. *Res Social Adm Pharm.*
407 2021;17(10):1685-1696. doi:<https://doi.org/10.1016/j.sapharm.2021.02.008>
- 408 35. World Health Organization (WHO). *Global Competency and Outcomes Framework for Universal Health Coverage.*
409 Geneva. Organization WH; 2022. <https://www.who.int/publications/i/item/9789240034662> Accessed 09-09-22.
- 410 36. International Pharmaceutical Federation (FIP). *FIP Global Humanitarian Competency Framework (GbHCF): Supporting*
411 *pharmacists and the pharmaceutical workforce in a humanitarian arena.* The Hague. International Pharmaceutical
412 Federation; 2021. <https://www.fip.org/file/5130>
- 413 37. Mestrovic A, Stanicic Z, Hadziabdic MO, et al. Evaluation of Croatian community pharmacists' patient care
414 competencies using the general level framework. *Am J Pharm Educ.* 2011;75(2):Article 36.

- 415 38. International Pharmaceutical Federation (FIP). *Transforming our workforce -Workforce development and education:*
416 *systems, tools and navigation*. The Hague. International Pharmaceutical Federation; 2016.
417 <https://www.fip.org/file/1392>
- 418 39. Al-Haqan A, Smith F, Bader L, Bates I. Competency development for pharmacy: Adopting and adapting the Global
419 Competency Framework. *Res Social Adm Pharm*. 2021;17(4):771-785.
420 doi:<https://doi.org/10.1016/j.sapharm.2020.06.023>
- 421 40. Siddiqui MA, Abdeldayem A, Abdel Dayem K, Mahomed SH, Diab MJJAJoH-SP. Pharmacy leadership during emergency
422 preparedness: Insights from the Middle East and South Asia. 2020;
- 423 41. Zhao Y, Diggs K, Ha D, Fish H, Beckner J, Westrick SC. Participation in emergency preparedness and response: a
424 national survey of pharmacists and pharmacist extenders. *J Am Pharm Assoc (2003)*. 2021;61(6):722-728.e1.
425 doi:<https://doi.org/10.1016/j.japh.2021.05.011>
- 426 42. Nuaimi N, Basheti IAJRiS, Pharmacy A. Pharmacists in humanitarian crisis settings: assessing the impact of pharmacist-
427 delivered home medication management review service to Syrian refugees in Jordan. 2019;15(2):164-172.
- 428 43. Aburas W, Alshammari TMJSPJ. Pharmacists' roles in emergency and disasters: COVID-19 as an example.
429 2020;28(12):1797-1816.
- 430 44. World Health Organization (WHO). Health workforce World Health Organization,. [https://www.who.int/health-](https://www.who.int/health-topics/health-workforce#tab=tab_1)
431 [topics/health-workforce#tab=tab_1](https://www.who.int/health-topics/health-workforce#tab=tab_1) (Accessed 17.07.22).
- 432 45. Thomson P, Jaque SV. Self-regulation, emotion, and resilience. In: Thomson P, Jaque SV, eds. *Creativity and the*
433 *Performing Artist*. Academic Press; 2017:225-243.
- 434 46. Zhao J, Zhang X, Du S. Factors associated with burnout and job satisfaction in Chinese hospital pharmacists. *Medicine*
435 *(Baltimore)*. 2020;99(35):e21919. doi:10.1097/md.00000000000021919
- 436 47. Meilianti S, Matuluko A, Ibrahim N, Uzman N, Bates I. A global study on job and career satisfaction of early-career
437 pharmacists and pharmaceutical scientists. *Exploratory Research in Clinical and Social Pharmacy*. 2022;5:100110.
438 doi:<https://doi.org/10.1016/j.rcsop.2022.100110>
- 439 48. Hall RH. Professionalization and bureaucratization. *Am Sociol Rev*. 1968:92-104.
- 440 49. World Health Organization (WHO). Mental disorders. World Health Organization. [https://www.who.int/news-](https://www.who.int/news-room/fact-sheets/detail/mental-disorders#:~:text=In%202019%2C%20in%20every,of%20the%20COVID%2D19%20pandemic)
441 [room/fact-sheets/detail/mental-](https://www.who.int/news-room/fact-sheets/detail/mental-disorders#:~:text=In%202019%2C%20in%20every,of%20the%20COVID%2D19%20pandemic)
442 [disorders#:~:text=In%202019%2C%20in%20every,of%20the%20COVID%2D19%20pandemic](https://www.who.int/news-room/fact-sheets/detail/mental-disorders#:~:text=In%202019%2C%20in%20every,of%20the%20COVID%2D19%20pandemic) (Accessed
443 10.06.2022).
- 444 50. Murphy AL, Martin-Misener R, Kutcher SP, O'Reilly CL, Chen TF, Gardner DM. From personal crisis care to convenience
445 shopping: an interpretive description of the experiences of people with mental illness and addictions in community
446 pharmacies. *BMC Health Serv Res*. 2016;16(1):569. doi:10.1186/s12913-016-1817-4
- 447 51. Law M, Bader L, Uzman N, Williams A, Bates I. The FIP Nanjing Statements: shaping global pharmacy and
448 pharmaceutical sciences education. *Res Social Adm Pharm*. 2019;doi:10.1016/j.sapharm.2019.03.013
- 449 52. Pharmaceutical Society of Ireland (PSI). *Core competency framework for pharmacists* 2013.
450 http://www.thepsi.ie/Libraries/Publications/PSI_Core_Competency_Framework_for_Pharmacists.sflb.ashx Accessed
451 24.06.22.
- 452 53. Almaghaslah D, Al-Haqan A, Al-jedai A, Alsayari A. Adopting global tools for the advancement of pharmacy practice
453 and workforce in Saudi Arabia. *Saudi Pharm J*. 2022;doi:<https://doi.org/10.1016/j.jsps.2022.05.007>
- 454

455 **Appendix 1**

456 Glossary of FIP-specific terms

| Term | Description |
|-------------------------------------|--|
| Competency (Competencies-plural) | Observable components of knowledge, skills, attitudes and values expressed as actual behaviour which can be measured and assessed |
| Competence | Capacity to perform job responsibilities (or pertaining to situations) effectively. |
| FIP DGs | Development goals for transforming global pharmacy across science, practice and workforce & education to support global health. |
| Workforce Development Hub (WDH) | FIP workforce development hub. |
| WDH director | Director of the FIP workforce development hub. |
| DG Lead/ WDH Lead | A pharmacy practitioner, academic or pharmaceutical scientist with an area of interest or expertise in any sector in pharmacy. |
| DG2 leads | A pharmacy practitioner, academic or pharmaceutical scientist with an area of interest or expertise in early career pharmacist development and training. |
| GbCF developer | Experts in the pharmacy field who first developed the GbCF in 2012 based on extensive literature search, content analysis, expert panels/focus groups and a global survey. |
| Expert Education Panel | A pharmacy academic, or pharmaceutical scientist, or education expert with an area of interest or expertise in early career pharmacist development and training. |
| Expert Practitioner Panel | A pharmacy practitioner or pharmaceutical scientist with an area of interest or expertise in early career pharmacist development and training. |
| External Review Panel | A pharmacy practitioner, academic or pharmaceutical scientist with an area of interest or expertise in any sector in pharmacy outside the FIP Hub/Boards/Sections/Groups. |

457

458

| Phase Expert groups (no) | Country | Region | Area of expertise |
|---|----------------|-----------------------|---|
| Internal review (Total no=18) | | | |
| DG4: Advanced and specialist development (n=3) | Indonesia | Asia | Academia, research in interprofessional education and training |
| | Australia | Western Pacific | Experiential training |
| | United Kingdom | Europe | Academia, research |
| DG6: Leadership development (n=3) | USA | America | Academia, research in leadership |
| | UK | Europe | Pharmaceutical public health |
| | USA | America | Academia, research in leadership |
| DG8: Working with others (n=3) | USA | America | Interprofessional education and curriculum development |
| | Switzerland | Europe | Interprofessional education |
| | Brazil | America | Academia and research |
| DG7: Advancing integrated services (n=3) | Lebanon | Eastern Mediterranean | Academia and research, practitioner |
| | South Africa | Africa | Professional development and support |
| | Germany | Europe | Academia, industrial research, and innovation |
| DG9: Continuing professional development (CPD) strategies (n=2) | Jordan | Eastern Mediterranean | Academia, research and quality assurance in pharmacy education. |
| | Australia | Europe | CPD and practice |
| DG11: Impact and outcomes (n=1) | Philippines | Western Pacific | Academia, workforce development and support |
| DG5: Competency development (n=3) | Australia | Western Pacific | Academia, research in workforce competency development |
| | UK | Europe | Academia, research in workforce competency development |
| | Croatia | Europe | CPD and quality assurance in pharmacy education |
| External review (Total n=11) | | | |
| | Netherlands | Europe | Data and intelligence |
| | Australia | Western Pacific | Academia, pharmacy practice and ethics |
| | Australia | Western Pacific | Academia, clinical pharmacy and competency development |
| | Australia | Western Pacific | Early career pharmacist training and development |
| | Australia | Western Pacific | Research – medicins safety |
| | Australia | Western Pacific | Research – pharmacy education and training |
| | UK | Europe | Academia and research |
| | Australia | Western Pacific | Research, clinical practice |

461

| | | | |
|--|-----------|-----------------|---|
| | Australia | Western Pacific | Pharmacy practice teaching, leadership and management |
| | Australia | Western Pacific | Post-graduate pharmacy education |
| | Australia | Western Pacific | Curriculum development, health services research |